Headlines about MannKind (NASDAQ:MNKD) have been trending somewhat positive recently, Accern Sentiment Analysis reports. Accern ranks the sentiment of media coverage by monitoring more than 20 million blog and news sources in real time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores closest to one being the most favorable. MannKind earned a news sentiment score of 0.18 on Accern’s scale. Accern also gave media coverage about the biopharmaceutical company an impact score of 44.7610224982077 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the stock’s share price in the next several days.

Several research firms have weighed in on MNKD. Zacks Investment Research cut MannKind from a “hold” rating to a “sell” rating in a research note on Wednesday. BidaskClub cut MannKind from a “buy” rating to a “hold” rating in a research note on Saturday, December 2nd. ValuEngine upgraded MannKind from a “strong sell” rating to a “sell” rating in a research note on Thursday, November 30th. Maxim Group restated a “hold” rating on shares of MannKind in a research note on Wednesday, November 1st. Finally, HC Wainwright restated a “buy” rating on shares of MannKind in a research note on Tuesday, October 24th. Four equities research analysts have rated the stock with a sell rating, two have given a hold rating and one has issued a buy rating to the company’s stock. The company presently has a consensus rating of “Hold” and an average price target of $0.92.

MannKind (NASDAQ MNKD) opened at $3.02 on Thursday. MannKind has a 12 month low of $0.67 and a 12 month high of $6.96. The company has a debt-to-equity ratio of -0.43, a quick ratio of 0.28 and a current ratio of 0.31.

MannKind (NASDAQ:MNKD) last announced its quarterly earnings results on Tuesday, November 7th. The biopharmaceutical company reported ($0.31) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.20) by ($0.11). MannKind had a negative net margin of 155.83% and a negative return on equity of 24.93%. The firm had revenue of $2.04 million during the quarter, compared to the consensus estimate of $2.56 million. During the same quarter in the previous year, the company posted $1.30 earnings per share. The firm’s revenue was down 98.7% on a year-over-year basis. analysts predict that MannKind will post -1.13 EPS for the current fiscal year.

In other news, Director Kent Kresa purchased 166,600 shares of the company’s stock in a transaction dated Friday, October 13th. The stock was bought at an average cost of $6.00 per share, for a total transaction of $999,600.00. The purchase was disclosed in a filing with the SEC, which is accessible through this hyperlink. 1.10% of the stock is currently owned by corporate insiders.

COPYRIGHT VIOLATION WARNING: This piece was originally posted by Watch List News and is the sole property of of Watch List News. If you are reading this piece on another website, it was illegally copied and reposted in violation of US & international copyright laws. The legal version of this piece can be read at https://www.watchlistnews.com/somewhat-positive-news-coverage-somewhat-unlikely-to-affect-mannkind-mnkd-stock-price/1762944.html.

About MannKind

MannKind Corporation is a biopharmaceutical company. The Company is focused on the discovery and development of therapeutic products for diseases, such as diabetes. Its product candidate is AFREZZA, which is an inhaled insulin used to control high blood sugar in adults with type I and type II diabetes and helps in glycemic control.

Insider Buying and Selling by Quarter for MannKind (NASDAQ:MNKD)

Receive News & Ratings for MannKind Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MannKind and related companies with MarketBeat.com's FREE daily email newsletter.